Compare TRDA & RELL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRDA | RELL |
|---|---|---|
| Founded | 2016 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electronic Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.3M | 248.1M |
| IPO Year | 2021 | 2004 |
| Metric | TRDA | RELL |
|---|---|---|
| Price | $4.60 | $18.87 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | $19.00 | ★ $25.50 |
| AVG Volume (30 Days) | ★ 327.2K | 296.8K |
| Earning Date | 11-05-2026 | 10-07-2026 |
| Dividend Yield | N/A | ★ 1.31% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $25,421,000.00 | ★ $228,564,000.00 |
| Revenue This Year | N/A | $12.68 |
| Revenue Next Year | $87.90 | $9.21 |
| P/E Ratio | ★ N/A | $230.96 |
| Revenue Growth | N/A | ★ 9.41 |
| 52 Week Low | $4.11 | $9.37 |
| 52 Week High | $16.45 | $23.15 |
| Indicator | TRDA | RELL |
|---|---|---|
| Relative Strength Index (RSI) | 34.84 | 51.24 |
| Support Level | N/A | $15.83 |
| Resistance Level | $7.89 | $19.40 |
| Average True Range (ATR) | 0.44 | 1.14 |
| MACD | -0.09 | -0.05 |
| Stochastic Oscillator | 28.53 | 38.78 |
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Richardson Electronics Ltd is a world-wide manufacturer of engineered solutions, green energy products, power grid and microwave tubes, and related consumables; power conversion and RF and microwave components including green energy solutions; tubes for diagnostic imaging equipment; and customized display solutions. It serve customers in alternative energy, healthcare, aviation, broadcast, communications, industrial, marine, medical, military, scientific, and semiconductor markets. Its products and services include design-in support, systems integration, prototype design and manufacturing, testing, logistics, etc. Its segments are Power and Microwave Technologies (PMT), Green Energy Solutions (GES), and Canvys. Majority of Sales is from PMT. Majority of sales is from North America.